Suzhou Connect Biopharmaceuticals, Ltd.
10th Floor, XiangTang Development Building
#3 ChaoYang Dong Road
About Suzhou Connect Biopharmaceuticals, Ltd.Suzhou Connect Biopharma is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. We identify and advance our drug candidates through in-house discovery and in-licensing, while leveraging qualified CROs for further development. We successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis. The randomized, double-blind, placebo controlled study assessed the tolerability, pharmacokinetics and pharmacodynamics of CBP-307 in Melbourne Australia, and CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. Meanwhile, we are advancing other preclinical programs including CBP-174 and CBP-201. CBP-174 is a small molecule inhibitor of a GPCR involved in allergic rhinitis and atopic dermatitis. This is an in-licensed program in which we hold exclusive global development and commercialization rights. CBP-201 is an internally-discovered monoclonal antibody for the treatment of asthma, atopic dermatitis and other diseases.
Founders: Zheng Wei and William (Wubin) Pan
Founder and CEO: Zheng Wei
Please click here for Connect Biopharma job opportunities.
Please click here for clinical trial information.
24 articles about Suzhou Connect Biopharmaceuticals, Ltd.
Connect Biopharma Holdings Limited announced that it will be hosting one-on-one investor meetings at the SVB Securities Therapeutics Forum, taking place on July 11-12, 2023 in New York, NY.
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
Connect Biopharma Holdings Limited announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
Connect Biopharma Holdings Limited announced that post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis showed that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, with both 2-week and 4-week dosing regimens, compared to placebo, as early as Week 2 and continuing through the 16-week study.
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
Connect Biopharma Holdings Limited today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023.
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, provided a business update for its operations and clinical trial development programs.
Connect Biopharma Holdings Limited announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences:
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
Connect Biopharma Holdings Limited announced topline results for the primary analysis population of the pivotal trial of the Company’s lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis in China.
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
Connect Biopharma Holdings Limited announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis.
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
Connect Biopharma Holdings Limited announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration, that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis based on the 255 patients already enrolled.
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022, Connect Biopharma Holdings Limited (the “Company”) received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”).
Connect Biopharma Holdings Limited announced that Dr. Zheng Wei, Co-Founder & Chief Executive Officer, and Steven Chan, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 am ET.
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
Connect Biopharma Phase II trial on a potential drug for adults with moderate-to-severe ulcerative colitis may have failed to meet its primary endpoint, but the company isn't giving up yet.
Connect Biopharma Holdings Limited announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET.
Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
Connect Biopharma Holdings Limited today announced that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief Business Officer, will be participating in fireside chats
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps
Connect Biopharma Holdings Limited announced that the first subject has been dosed in a Phase 2 trial evaluating CBP-201 in adult patients with chronic rhinosinusitis with nasal polyps.
Connect Biopharma Holdings Limited today announced that it will report financial results for the first half ended June 30, 2021 after the market closes on Tuesday, August 31, 2021.
Connect Biopharma Holdings Limited today announced Mr. Jiang Bian has joined the Company as General Counsel & Chief Compliance Officer, effective August 20, 2021.
Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced that the first subject has been dosed in a Phase I trial evaluating CBP-174 in healthy adult subjects.